Yearly Archives

2019

Today is World Down Syndrome Day!

By | Commentary | No Comments

Did you know that people with Down syndrome are at significantly increased risk to develop Alzheimer’s disease? UCI MIND researchers, like Ira Lott, MD, Eric Doran, MS, Elizabeth Head, PhD, and Jorge Busciglio, PhD aim to better understand this critical link to improve quality of life and bring us closer to improved treatments and prevention for all people impacted by Alzheimer’s disease. To learn more about the UCI MIND Down Syndrome Program, click here > To read a recent interview with Down Syndrome Program manager, Eric Doran, click here >. In this post, Eric discusses the creation of a new…

Read More

Phase 3 Trials of Aducanumab Halted

By | Commentary, In the News | No Comments

Contributed by Joshua Grill, PhD, Director of UCI MIND The global research effort to find effective treatments for Alzheimer’s disease has suffered another disappointing setback. Biogen announced today that the company will halt the parallel large Phase 3 trials of the monoclonal antibody against the amyloid beta protein, aducanumab. This treatment was viewed by many to hold tremendous promise. Early results were unprecedented. Patients with Alzheimer’s disease who were treated with aducanumab showed significant reduction in amyloid burden in the brain, which appeared to slow disease progression. The results were based on a small number of participants, however, and were not…

Read More

Participants are needed for a new Alzheimer’s disease clinical trial at UC Irvine and UCLA.

By | Commentary | No Comments

People ages 50 and older who have memory problems are needed for a new clinical trial for Mild Cognitive Impairment and Alzheimer’s disease at the University of California, Los Angeles and University of California, Irvine. The NEAT study is a clinical trial sponsored by the University of California “Cures for Alzheimer’s Initiative,” testing whether nicotinamide, a component of vitamin B3, can slow Alzheimer’s disease. Specifically, the 12-month study is investigating if a high daily dose of nicotinamide can affect the brain tangles associated with Alzheimer’s disease. The study also measures whether nicotinamide is effective in improving memory and other thinking…

Read More

Forgetful Yet Unforgettable: The Legacy of an Alzheimer’s Patient

By | Commentary, In the News | No Comments

In an interview with UCI undergraduate students, Chelsea Cox, Associate Director of Eduction for UCI MIND, shares her personal journey with Alzheimer’s disease, her perspective on care and research, and how people – young and old – can get involved in the cause. “…No one should have to spend their final days that way. This experience is what motivated me to get involved in Alzheimer’s research and education. So that hopefully, one day, other people don’t have to go through what my family went through.” Read the full interview on Medium >

Read More

What causes memory problems in older adults?

By | Community Events | No Comments

Tune in this Friday, March 1 @ 9AM for the next episode of our monthly Facebook LIVE series, “What causes memory problems in older adults?” This month, we’re joined by Ahmad Sajjadi, MD, PhD, Assistant Professor of Neurology in the UCI School of Medicine. Dr. Sajjadi received his medical degree from Tehran University of Medical Sciences in Iran and his PhD from the University of Cambridge in the UK. Dr. Sajjadi is a behavioral neurologist who sees patients with memory concerns and also conducts research on Alzheimer’s disease and atypical forms of dementia. To attend live and ask questions, login…

Read More

FDA issues warning to dietary supplements making unproven claims

By | Commentary, In the News | No Comments

On February 11, the FDA issued a statement and 12 warning letters related to an aggressive change in the agency’s regulation of dietary supplements. The statement was outlined in the New York Times. The main objective of the new approach is enhanced protection of consumers from mislabeled and unproven claims about treatment of disease. At the core of the problem are a number of companies that specifically target people with Alzheimer’s disease and people who are concerned about developing Alzheimer’s disease. A list of the companies receiving warning letters, as well as links to the letters, can be found here.

Read More